A STUDY OF THE TUMOR-TARGETING HUMAN F16IL2 MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN IN COMBINATION WITH VERY LOW-DOSE CYTARABINE IN PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: